Signet Financial Management LLC reduced its position in Celgene Corporation (NASDAQ:CELG) by 0.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 32,116 shares of the biopharmaceutical company’s stock after selling 67 shares during the period. Signet Financial Management LLC’s holdings in Celgene were worth $4,170,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Capital Counsel LLC NY raised its holdings in Celgene by 0.4% in the 2nd quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 6 shares during the last quarter. Sowell Financial Services LLC grew its position in Celgene by 0.5% in the 1st quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 13 shares during the period. South Texas Money Management Ltd. grew its position in Celgene by 0.6% in the 1st quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 15 shares during the period. Flagship Harbor Advisors LLC grew its position in Celgene by 0.9% in the 1st quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock worth $253,000 after purchasing an additional 18 shares during the period. Finally, Savant Capital LLC grew its position in Celgene by 0.9% in the 2nd quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 20 shares during the period. Institutional investors own 80.17% of the company’s stock.

A number of equities research analysts have commented on CELG shares. Morgan Stanley downgraded shares of Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 target price for the company. in a research report on Thursday, October 5th. BTIG Research reaffirmed a “hold” rating on shares of Celgene in a research report on Sunday, October 22nd. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $112.00 target price on shares of Celgene in a research report on Monday, October 30th. Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 target price for the company in a research report on Monday, October 23rd. Finally, Oppenheimer set a $166.00 target price on shares of Celgene and gave the stock a “buy” rating in a research report on Thursday, November 16th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have issued a buy rating and two have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $139.57.

Shares of Celgene Corporation (NASDAQ:CELG) opened at $102.17 on Thursday. Celgene Corporation has a 1 year low of $94.55 and a 1 year high of $147.17. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. The stock has a market cap of $80,747.23, a price-to-earnings ratio of 16.02, a PEG ratio of 0.79 and a beta of 1.78.

Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter in the previous year, the firm posted $1.58 EPS. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. sell-side analysts forecast that Celgene Corporation will post 6.67 earnings per share for the current year.

In related news, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the transaction, the director now directly owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. Corporate insiders own 0.95% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/celgene-corporation-celg-position-trimmed-by-signet-financial-management-llc/1748999.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.